[go: up one dir, main page]

WO2003033527A3 - Cyclosporine analogue mixtures and their use as immunomodulating agents - Google Patents

Cyclosporine analogue mixtures and their use as immunomodulating agents Download PDF

Info

Publication number
WO2003033527A3
WO2003033527A3 PCT/CA2002/001560 CA0201560W WO03033527A3 WO 2003033527 A3 WO2003033527 A3 WO 2003033527A3 CA 0201560 W CA0201560 W CA 0201560W WO 03033527 A3 WO03033527 A3 WO 03033527A3
Authority
WO
WIPO (PCT)
Prior art keywords
isomers
cyclosporine
mixtures
isatx247
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2002/001560
Other languages
French (fr)
Other versions
WO2003033527A2 (en
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isotechnika Inc
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL16076202A priority Critical patent/IL160762A0/en
Priority to EP02767028A priority patent/EP1436322B1/en
Priority to HRP20040353AA priority patent/HRP20040353B1/en
Priority to DE60227686T priority patent/DE60227686D1/en
Priority to BR0213659-7A priority patent/BR0213659A/en
Priority to MEP-2008-780A priority patent/ME00487B/en
Priority to JP2003536265A priority patent/JP2005511538A/en
Priority to CA2460685A priority patent/CA2460685C/en
Priority to SI200230742T priority patent/SI1436322T1/en
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Priority to MXPA04003624A priority patent/MXPA04003624A/en
Priority to AU2002331510A priority patent/AU2002331510B2/en
Priority to HK04105424.1A priority patent/HK1062567B/en
Priority to NZ531945A priority patent/NZ531945A/en
Priority to DK02767028T priority patent/DK1436322T3/en
Publication of WO2003033527A2 publication Critical patent/WO2003033527A2/en
Publication of WO2003033527A3 publication Critical patent/WO2003033527A3/en
Priority to IL160762A priority patent/IL160762A/en
Priority to ZA2004/02270A priority patent/ZA200402270B/en
Priority to TNP2004000069A priority patent/TNSN04069A1/en
Anticipated expiration legal-status Critical
Priority to NO20042029A priority patent/NO331745B1/en
Priority to CY20081101130T priority patent/CY1108410T1/en
Priority to NO2022042C priority patent/NO2022042I1/en
Priority to BE2022C547C priority patent/BE2022C547I2/nl
Priority to CY2022030C priority patent/CY2022030I2/en
Priority to LTPA2022521C priority patent/LTC1436322I2/lt
Priority to NL301200C priority patent/NL301200I2/en
Priority to FR22C1051C priority patent/FR22C1051I2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A . The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
PCT/CA2002/001560 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents Ceased WO2003033527A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
DK02767028T DK1436322T3 (en) 2001-10-19 2002-10-17 Mixtures of cyclosporin analogs and their use as immunomodulatory agents
HRP20040353AA HRP20040353B1 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
DE60227686T DE60227686D1 (en) 2001-10-19 2002-10-17 MIXTURES OF CYCLOSPORIN ANALOGS AND THEIR USE AS IMMUNOMODULATORS
BR0213659-7A BR0213659A (en) 2001-10-19 2002-10-17 Composition, pharmaceutical composition, method for producing immunosuppression, method for reducing toxicity, method for increasing the efficiency of an immunosuppressive analogue, composition use, and mixture use
MEP-2008-780A ME00487B (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
JP2003536265A JP2005511538A (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulators
CA2460685A CA2460685C (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
SI200230742T SI1436322T1 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
EP02767028A EP1436322B1 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
MXPA04003624A MXPA04003624A (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents.
AU2002331510A AU2002331510B2 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
HK04105424.1A HK1062567B (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
NZ531945A NZ531945A (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents
IL16076202A IL160762A0 (en) 2001-10-19 2002-10-17 Cyclosporin analogue mixtures and their use as immunomodulating agents
IL160762A IL160762A (en) 2001-10-19 2004-03-05 Cyclosporin analogue mixtures and their use as immunomodulating agents
ZA2004/02270A ZA200402270B (en) 2001-10-19 2004-03-23 Cyclosporine analogue mixtures and their use as immunomodulating agents
TNP2004000069A TNSN04069A1 (en) 2001-10-19 2004-04-16 Cyclosporine analogue mixtures and their use as immunomodulating agents
NO20042029A NO331745B1 (en) 2001-10-19 2004-05-14 Mixtures of cyclosporin analogs and their use as immunomodulatory compounds
CY20081101130T CY1108410T1 (en) 2001-10-19 2008-10-13 MIXTURES OF CYCLOSPORINE ANALOGUES AND THEIR USE AS IMMUNO-REGULATORS
FR22C1051C FR22C1051I2 (en) 2001-10-19 2022-10-14 MIXTURES OF CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
NO2022042C NO2022042I1 (en) 2001-10-19 2022-10-14 Voclosporin, a calcineurin inhibitor, its salts and esters
NL301200C NL301200I2 (en) 2001-10-19 2022-10-14 Voclosporin
BE2022C547C BE2022C547I2 (en) 2001-10-19 2022-10-14
CY2022030C CY2022030I2 (en) 2001-10-19 2022-10-14 MIXTURES OF CYCLOSPORINE ANALOGUES AND THEIR USE AS IMMUNOSUPPRESSORS
LTPA2022521C LTC1436322I2 (en) 2001-10-19 2022-10-14

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US60/346,201 2001-10-19

Publications (2)

Publication Number Publication Date
WO2003033527A2 WO2003033527A2 (en) 2003-04-24
WO2003033527A3 true WO2003033527A3 (en) 2003-10-16

Family

ID=23358378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001560 Ceased WO2003033527A2 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents

Country Status (37)

Country Link
US (2) US20110092669A1 (en)
EP (2) EP1436322B1 (en)
JP (4) JP2005511538A (en)
KR (1) KR100992850B1 (en)
CN (1) CN100344648C (en)
AR (1) AR036853A1 (en)
AT (1) ATE401339T1 (en)
AU (1) AU2002331510B2 (en)
BE (1) BE2022C547I2 (en)
BR (1) BR0213659A (en)
CA (2) CA2460685C (en)
CO (1) CO5570682A2 (en)
CY (2) CY1108410T1 (en)
DE (1) DE60227686D1 (en)
DK (1) DK1436322T3 (en)
EC (3) ECSP045061A (en)
ES (1) ES2310604T3 (en)
FI (1) FIC20220041I1 (en)
FR (1) FR22C1051I2 (en)
HR (1) HRP20040353B1 (en)
IL (2) IL160762A0 (en)
LT (1) LTC1436322I2 (en)
MA (1) MA26337A1 (en)
ME (1) ME00487B (en)
MX (1) MXPA04003624A (en)
MY (1) MY187182A (en)
NL (1) NL301200I2 (en)
NO (2) NO331745B1 (en)
NZ (1) NZ531945A (en)
PL (1) PL210697B1 (en)
PT (1) PT1436322E (en)
RU (1) RU2337106C2 (en)
SI (1) SI1436322T1 (en)
TN (1) TNSN04069A1 (en)
UY (1) UY27502A1 (en)
WO (1) WO2003033527A2 (en)
ZA (1) ZA200402270B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460685C (en) * 2001-10-19 2014-05-27 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1812037A4 (en) 2004-10-06 2009-11-11 Amr Technology Inc Novel cyclosporin alkynes and their utility as pharmaceutical agents
CA2592343A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
BRPI0617781A2 (en) * 2005-10-26 2011-08-09 Astellas Pharma Inc cyclic peptide compounds
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
MX2009011512A (en) * 2007-05-02 2009-11-12 Astellas Pharma Inc New cyclic peptide compounds.
CA2701482C (en) 2007-10-08 2018-10-23 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
RU2361604C1 (en) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Way of treatment of atopic dermatitis
ES2537385T3 (en) 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Topical supply systems for ophthalmic use
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
WO2018102565A1 (en) * 2016-11-30 2018-06-07 Schrödinger, Inc. Graphical user interface for chemical transition state calculations
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3172601A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Preparation of cyclosporin derivatives
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
EP4584279A1 (en) * 2022-09-09 2025-07-16 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001116A1 (en) * 2023-01-25 2024-07-25 Indena Spa PROCESS FOR THE PREPARATION OF AN INTERMEDIATE USEFUL FOR THE SYNTHESIS OF VOCLOSPORIN
IT202300001056A1 (en) * 2023-01-25 2024-07-25 Procos Spa NEW PROCESS FOR PREPARATION OF AMORPHOUS VOCLOSPORIN
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
WO2025141456A1 (en) * 2023-12-27 2025-07-03 Indena S.P.A. Process for the preparation of voclosporin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296122A2 (en) * 1987-06-17 1988-12-21 Sandoz Ag Cyclosporins and their use as pharmaceuticals
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278545A (en) * 1979-09-12 1981-07-14 The Bendix Corporation Apparatus for separating solids and liquid components
CH670644A5 (en) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
KR20000016761A (en) * 1996-06-19 2000-03-25 멘레 코르넬리아, 발데그 베르너 Cyclosporin-containing soft capsule preparations
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
DE60231570D1 (en) * 2001-10-19 2009-04-23 Isotechnika Inc Synthesis of Cyclosporin Analogs
CA2460685C (en) * 2001-10-19 2014-05-27 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296122A2 (en) * 1987-06-17 1988-12-21 Sandoz Ag Cyclosporins and their use as pharmaceuticals
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASPESLET L ET AL.: "ISATX247: A Novel Calcineurin Inhibitor", TRANSPLANTATION PROCEEDINGS, vol. 33, February 2001 (2001-02-01), pages 1048 - 1051, XP001162707 *
EBERLE M K ET AL: "Modifications of the MeBmt Side Chain of Cyclosporin A", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 15, 3 August 1995 (1995-08-03), pages 1725 - 1728, XP004135415, ISSN: 0960-894X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins

Also Published As

Publication number Publication date
BR0213659A (en) 2004-10-26
FR22C1051I2 (en) 2023-11-17
TNSN04069A1 (en) 2006-06-01
HK1062567A1 (en) 2004-11-12
KR100992850B1 (en) 2010-11-09
MA26337A1 (en) 2004-10-01
CY2022030I1 (en) 2023-01-27
JP2013136597A (en) 2013-07-11
KR20050037421A (en) 2005-04-21
MXPA04003624A (en) 2004-12-06
DE60227686D1 (en) 2008-08-28
RU2337106C2 (en) 2008-10-27
CY2022030I2 (en) 2023-06-09
IL160762A (en) 2010-11-30
ATE401339T1 (en) 2008-08-15
RU2004110941A (en) 2005-08-10
ES2310604T3 (en) 2009-01-16
JP2005511538A (en) 2005-04-28
EP1816138A1 (en) 2007-08-08
WO2003033527A2 (en) 2003-04-24
CA2460685A1 (en) 2003-04-24
ECSP045059A (en) 2004-07-23
LTPA2022521I1 (en) 2022-11-10
HRP20040353B1 (en) 2012-10-31
FR22C1051I1 (en) 2022-12-16
ME00487B (en) 2011-10-10
IL160762A0 (en) 2004-08-31
US20140288266A1 (en) 2014-09-25
UY27502A1 (en) 2003-04-30
ZA200402270B (en) 2005-05-25
NO20042029L (en) 2004-05-14
LTC1436322I2 (en) 2023-06-26
FIC20220041I1 (en) 2022-10-14
JP2011006417A (en) 2011-01-13
SI1436322T1 (en) 2008-12-31
NL301200I2 (en) 2024-07-25
ECSP045060A (en) 2004-07-23
CA2727642A1 (en) 2003-04-24
NO2022042I1 (en) 2022-10-14
NO331745B1 (en) 2012-03-19
CY1108410T1 (en) 2012-05-23
BE2022C547I2 (en) 2022-10-19
PL370501A1 (en) 2005-05-30
ECSP045061A (en) 2004-08-27
EP1436322A2 (en) 2004-07-14
EP1436322B1 (en) 2008-07-16
PL210697B1 (en) 2012-02-29
CN1571794A (en) 2005-01-26
JP2009197036A (en) 2009-09-03
CO5570682A2 (en) 2005-10-31
CA2460685C (en) 2014-05-27
NZ531945A (en) 2006-01-27
HRP20040353A2 (en) 2005-04-30
DK1436322T3 (en) 2008-11-03
JP5272140B2 (en) 2013-08-28
CN100344648C (en) 2007-10-24
MY187182A (en) 2021-09-08
CA2727642C (en) 2014-02-04
PT1436322E (en) 2008-10-23
AR036853A1 (en) 2004-10-06
US20110092669A1 (en) 2011-04-21
AU2002331510B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
WO2003033527A3 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
WO2003033526A3 (en) Synthesis of cyclosporin analogs
BR9808656A (en) Hydrophilic binary systems for the administration of cyclosporine
MY145753A (en) Novel cyclosporin analog formulations
WO2001049314A3 (en) Glp-2 formulations
JO2034B1 (en) LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
ZA985142B (en) Captopril retard.
YU33204A (en) Synthesis of cyclosporin analogs
YU33004A (en) Cyclosporine analogue mixtures and their use as immuno modulating agents
WO2001013895A3 (en) Controlled-release sedative-hypnotic compositions and methods related thereto
AU2002231771A1 (en) Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
CA2400728A1 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200400330

Country of ref document: VN

Ref document number: P-330/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160762

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 697/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/02270

Country of ref document: ZA

Ref document number: 2002331510

Country of ref document: AU

Ref document number: 200402270

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 531945

Country of ref document: NZ

Ref document number: 2460685

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002767028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500458

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003536265

Country of ref document: JP

Ref document number: PA/a/2004/003624

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047005721

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20040353A

Country of ref document: HR

Ref document number: 2002820798X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002767028

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 531945

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 531945

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002767028

Country of ref document: EP